Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (T32 GM007750, R01GM111772)
U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (R24 HD000836)
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (TL1 TR000422)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (DA032507)
Article History
Received: 5 October 2018
Accepted: 21 February 2019
First Online: 15 March 2019
Competing Interests
: Nina Isoherranen holds a US Patent number: 9963439 on CYP26 Inhibitors. She has received honorariums from Pfizer and Genentech and is a consultant for Boehringer Ingleheim. Ariel Topletz is currently an employee of Seattle Genetics.